Who buys J Alexander's (Jax)?
JAX stock was bought by a variety of institutional investors in the last quarter, including OLD Mission Capital LLC. Company insiders that have bought J. Alexander's stock in the last two years include Jessica Leigh Hagler, Lonnie J Stout II, and Mark A Parkey.
What is the ticker symbol for J Alexander's?
J. Alexander's trades on the New York Stock Exchange (NYSE) under the ticker symbol "JAX." Who are J. Alexander's' major shareholders? J. Alexander's' stock is owned by a variety of retail and institutional investors.
Who owns J Alexander's'stock?
J. Alexander's' stock is owned by a variety of retail and institutional investors. Top institutional investors include Crescent Grove Advisors LLC (0.66%), Ancora Advisors LLC (0.09%) and OLD Mission Capital LLC (0.08%). Company insiders that own J. Alexander's stock include Jessica Leigh Hagler, Lonnie J Stout II and Mark A Parkey.
What is the PE (price/earnings) ratio of J Alexander's?
The P/E ratio of J. Alexander's is 26.42, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 14.49. The P/E ratio of J. Alexander's is 26.42, which means that it is trading at a less expensive P/E ratio than the Retail/Wholesale sector average P/E ratio of about 26.55.
Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference
SAN DIEGO, January 05, 2022--Janux Therapeutics, Inc.
We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results
SAN DIEGO, November 09, 2021--Janux Therapeutics, Inc.
Janux Therapeutics to Present Virtually at Upcoming Investor Conferences
SAN DIEGO, November 08, 2021--Janux Therapeutics, Inc.
Janux Therapeutics Appoints Ron Barrett, Ph.D., and Alana McNulty to Board of Directors
SAN DIEGO, September 09, 2021--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the additions of Ronald W.
Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference
SAN DIEGO, September 07, 2021--Janux Therapeutics, Inc.
Janux Therapeutics Appoints Shahram Salek-Ardakani, Ph.D., Chief Scientific Officer
SAN DIEGO, July 19, 2021--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the appointment of Shahram Salek-Ardakani, Ph.D., as Chief Scientific Officer. Dr.
Jaguar Animal Health Seeks MUMS Designation from FDA for Canalevia (Crofelemer) for Treatment of Exercise-induced Diarrhea (EID) in Dogs
In December of 2021, FDA conditionally approved Canalevia™-CA1 for treatment of chemotherapy-induced diarrhea in dogs, and the company expects Canalevia could receive FDA conditional approval, under the name Canalevia™-CA2, for treatment of EID in dogsSAN FRANCISCO, CA / ACCESSWIRE / February 16, 2022 / Jaguar Health, Inc.
Jaguar Health Announces Receipt by Napo Therapeutics of Small and Medium Enterprise (SME) Designation from the European Medicines Agency
SME status is an important designation for Italy-based Napo Therapeutics' rare/orphan disease business modelSAN FRANCISCO, CA and MILAN, ITALY / ACCESSWIRE / February 15, 2022 / Jaguar Health (NASDAQ:JAGX) and Napo Therapeutics S., an Italian corporation established by Jaguar Health in Milan, Italy, today announced that Napo Therapeutics has been granted Small and Medium Enterprise (SME) designation by the European Medicines Agency (EMA)..
Jaguar Health Completes Final Major Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in Dogs
Canalevia™ would be first and only FDA-approved plant-based medicine for working dogs that suffer from diarrheaSAN FRANCISCO, CA / ACCESSWIRE / February 10, 2022 / Jaguar Health, Inc.